Panithaya Chareonthaitawee

6 days ago | jnm.snmjournals.org | Thomas Schindler |Timothy M. Bateman |Daniel Berman |Panithaya Chareonthaitawee

Recently, the U.S. Food and Drug Administration (FDA) approved 18F-labeled flurpiridaz as another PET myocardial perfusion imaging (MPI) radiotracer for clinical use in adult patients with known or suspected coronary artery disease (CAD). This decision was based on recent results of a second phase 3 prospective multicenter clinical trial (1) and prior trials (2,3).